India’s contract drug manufacturing sector is calling for regulatory reforms and expedited clearances for raw material imports to strengthen its position in the global pharmaceutical supply chain. The Contract Research Development and Manufacturing Organisation (CRDMO) industry, which could grow seven-fold to $22-25 billion by 2035, faces delays due to prolonged Continue Reading
